30 results
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
15 Aug 24
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
8:40am
portfolio of innovative product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA YS-ON-001, and PIKA YS-HBV-002
424B3
LSB
LakeShore Biopharma Co., Ltd
8 May 24
Prospectus supplement
8:32am
”), an investment management firm which invests in innovative growth companies within the TMT and healthcare sectors in both China and the United States … customers in China since October 2020.
Clinical Pipeline
YS Biopharma continues to prioritize and advance its portfolio of innovative product
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
7 May 24
Report of Foreign Private Issuer
4:30pm
growth within these sectors. In 2018, he founded Oceanpine Capital (“Oceanpine”), an investment management firm which invests in innovative growth
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
19 Apr 24
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
8:03am
continues to prioritize and advance its portfolio of innovative product candidates under various clinical development stages, including PIKA rabies
6-K
EX-99.1
xve1snsv al5h7l7s8az
18 Apr 24
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
8:15am
6-K
EX-99.1
aq6wmaf75v4vw4hw6vcs
9 Apr 24
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
8:20am
POS AM
n6raqi
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
6-K
EX-99.1
yrftfq
22 Jan 24
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
5:10pm
424B3
w7h9b2a4ad85
26 Sep 23
Prospectus supplement
9:13am
6-K
EX-99.1
lti0umeg
26 Sep 23
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
9:10am
424B3
x0p8a
25 Sep 23
Prospectus supplement
6:12am
424B3
ii5jc1cospznjs
25 Sep 23
Prospectus supplement
6:07am
6-K
EX-99.1
zse1rtu7
25 Aug 23
YS Biopharma Announces Purchase of Shares by Company Officers
8:00am
6-K
EX-99.1
60sxptzfl
16 Aug 23
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
8:00am
424B3
qeq27m qe
15 Aug 23
Prospectus supplement
8:00am
POS AM
6l3jjo b8hcju1jrf3
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
20-F
dlhffr7z0 u8xt
26 Jul 23
Annual report (foreign)
4:02pm
424B3
9pbl yvuy
5 Jun 23
Prospectus supplement
4:03pm
6-K
EX-99.1
a97ui8 c7mi
16 May 23
YS Biopharma’s PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
10:38am